Outcomes of Short-Term Tigecycline-Containing Regimens for Mycobacterium abscessus Pulmonary Disease

Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0077422. doi: 10.1128/aac.00774-22. Epub 2022 Sep 27.

Abstract

Short-term intravenous tigecycline therapy during a 1-month initial phase may improve early microbiological response in patients with Mycobacterium abscessus pulmonary disease (PD). However, short-term use of tigecycline did not improve the long-term culture conversion rate of M. abscessus PD. Further studies on the efficacy of prolonged intravenous tigecycline-containing regimens are needed.

Keywords: Mycobacterium abscessus; tigecycline; treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Humans
  • Lung Diseases* / drug therapy
  • Microbial Sensitivity Tests
  • Mycobacterium Infections, Nontuberculous* / drug therapy
  • Mycobacterium Infections, Nontuberculous* / microbiology
  • Mycobacterium abscessus*
  • Tigecycline / therapeutic use

Substances

  • Tigecycline
  • Anti-Bacterial Agents